GlassScriptPhysician profile
Rehan Zahid
NPI 1144831975
$57,194.97
in general payments reported to CMS, 2019-2025
9 companies · $1,529 in 2025
The $1,529 reported for 2025 was more than what 79% of Plastic and Reconstructive Surgery providers received nationally (typical 2025 total: $445).
See the full distribution for Plastic and Reconstructive Surgery
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $121 · 2021: $23K · 2022: $33K · 2023: $137 · 2024: $285 · 2025: $1,529.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,229 · Travel and Lodging: $722.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,229.22 |
| Travel and Lodging | $722.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kls-Martin L.P. | $52,500.00 | 2021-2022 | |
| Alpha Orthopedic Systems | $2,409.48 | 2021 | |
| Axogen | $1,725.87 | 2020-2025 | Avance Nerve Graft |
| Mentor Worldwide LLC | $189.30 | 2024 | Mentor Cpx 2 Breast Tissue Expander |
| Medartis INC. | $141.80 | 2021 | |
| Abbvie INC. | $95.70 | 2024 | |
| Ossur Americas, INC. | $85.95 | 2025 | I-Limb |
| Endo Pharmaceuticals INC. | $24.29 | 2020-2021 | |
| Medline Industries LP | $22.58 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rehan Zahid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.